Canada markets closed

Sernova Corp. (PSH.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.2088+0.0196 (+10.36%)
At close: 05:38PM CEST

Sernova Corp.

The Stiller Centre
Suite 114 700 Collip Circle
London, ON N6G 4X8
Canada
519 858 5126
https://www.sernova.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Ms. Cynthia PussinenCEO & Director369.92kN/AN/A
Dr. Modestus Obochi M.B.A., Ph.D.Chief Business Officer202.6kN/AN/A
Dr. Frank Shannon M.D.Vice President of Clinical Development & Regulatory Affairs234.17kN/AN/A
Mr. Nicholas J. Rossettos CPA, M.B.A.Interim Chief Financial OfficerN/AN/A1966
Mr. Douglas MaretChief Science OfficerN/AN/AN/A
Mr. Christopher BarnesVice President of Investor Relations109.81kN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.

Corporate Governance

Sernova Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.